Correlation between CTBP2 expression and clinico-pathological parameters in the MMRF CoMMpass trial IA11 release
| Clinical parameters . | Low CTBP2 (n = 141) . | High CTBP2 (n = 604) . | Overall (n = 745) . | 2-sided P value . |
|---|---|---|---|---|
| Age at diagnosis | ||||
| <65 | 78/141 (55.3%) | 336/604 (55.6%) | 414/745 (55.6%) | 1.000 |
| ≥65 | 63/141 (44.7%) | 268/604 (44.4%) | 331/745 (44.4%) | |
| Gender | ||||
| Male | 80/141 (56.7%) | 361/604 (59.8%) | 441/745 (59.2%) | .507 |
| Female | 61/141 (43.3%) | 243/604 (40.2%) | 304/745 (40.8%) | |
| ISS stage | ||||
| I | 36/136 (26.5%) | 215/588 (36.6%) | 251/724 (34.7%) | .082 |
| II | 55/136 (40.4%) | 209/588 (35.5%) | 264/724 (36.5%) | |
| III | 45/136 (33.1%) | 164/588 (27.9%) | 209/724 (28.9%) | |
| β2-microglobulin (≥5.5 mg) | 45/135 (33.3%) | 163/585 (27.9%) | 208/720 (28.9%) | .208 |
| Albumin (≥3.5 mg/L) | 79/141 (59.6%) | 365/604 (60.4%) | 444/745 (59.6%) | .342 |
| Hypercalcemia (≥12 mg/dL) | 6/141 (4.3%) | 25/604 (4.1%) | 31/745 (4.2%) | 1.000 |
| LDH (≥190 U/L) | 46/107 (43%) | 176/483 (36.4%) | 222/590 (37.36%) | .225 |
| Creatinine (≥2.0 mg/dL) | 11/141 (7.8%) | 67/604 (11.1%) | 78/745 (10.5%) | .287 |
| Hb (<10 g/dL) | 68/141 (48.2%) | 218/604 (36.1%) | 286/745 (38.4%) | .008∗ |
| BMPC (%) | 26.6 (2-88) | 17.1 (0-91) | 16.0 (0-94) | <.001∗ |
| M protein (g/dL) | 3.38 (0-9.98) | 2.97 (0-12.27) | 3.0 (0-12.27) | .048∗ |
| Cytogenetic abnormalities | ||||
| Deletion of 17p13 | 6/87 (6.9%) | 46/348 (13.2%) | 52/435 (12.0%) | .138 |
| t(4;14) | 22/103 (21.4%) | 75/421 (17.8%) | 97/524 (18.5%) | .399 |
| t(8;14) | 2/56 (3.6%) | 3/195 (1.5%) | 5/251 (2%) | .310 |
| t(14;16) | 17/91 (18.7%) | 34/391 (8.7%) | 51/482 (10.6%) | .008∗ |
| t(14;20) | 2/69 (2.9%) | 6/265 (2.3%) | 8/334 (2.4%) | .671 |
| Amplification of 1q | 43/85 (50.6) | 127/369 (34.4%) | 170/454 (37.4%) | .006∗ |
| Deletion of 1p | 6/75 (8%) | 46/351 (13.1%) | 52/426 (12.2%) | .250 |
| Deletion of 13q | 32/101 (31.7%) | 106/392 (27.0%) | 138/493 (28.0%) | .385 |
| Nonhyperdiploid | 105/123 (85.4%) | 467/525 (89.0%) | 572/648 (88.3%) | .277 |
| Clinical parameters . | Low CTBP2 (n = 141) . | High CTBP2 (n = 604) . | Overall (n = 745) . | 2-sided P value . |
|---|---|---|---|---|
| Age at diagnosis | ||||
| <65 | 78/141 (55.3%) | 336/604 (55.6%) | 414/745 (55.6%) | 1.000 |
| ≥65 | 63/141 (44.7%) | 268/604 (44.4%) | 331/745 (44.4%) | |
| Gender | ||||
| Male | 80/141 (56.7%) | 361/604 (59.8%) | 441/745 (59.2%) | .507 |
| Female | 61/141 (43.3%) | 243/604 (40.2%) | 304/745 (40.8%) | |
| ISS stage | ||||
| I | 36/136 (26.5%) | 215/588 (36.6%) | 251/724 (34.7%) | .082 |
| II | 55/136 (40.4%) | 209/588 (35.5%) | 264/724 (36.5%) | |
| III | 45/136 (33.1%) | 164/588 (27.9%) | 209/724 (28.9%) | |
| β2-microglobulin (≥5.5 mg) | 45/135 (33.3%) | 163/585 (27.9%) | 208/720 (28.9%) | .208 |
| Albumin (≥3.5 mg/L) | 79/141 (59.6%) | 365/604 (60.4%) | 444/745 (59.6%) | .342 |
| Hypercalcemia (≥12 mg/dL) | 6/141 (4.3%) | 25/604 (4.1%) | 31/745 (4.2%) | 1.000 |
| LDH (≥190 U/L) | 46/107 (43%) | 176/483 (36.4%) | 222/590 (37.36%) | .225 |
| Creatinine (≥2.0 mg/dL) | 11/141 (7.8%) | 67/604 (11.1%) | 78/745 (10.5%) | .287 |
| Hb (<10 g/dL) | 68/141 (48.2%) | 218/604 (36.1%) | 286/745 (38.4%) | .008∗ |
| BMPC (%) | 26.6 (2-88) | 17.1 (0-91) | 16.0 (0-94) | <.001∗ |
| M protein (g/dL) | 3.38 (0-9.98) | 2.97 (0-12.27) | 3.0 (0-12.27) | .048∗ |
| Cytogenetic abnormalities | ||||
| Deletion of 17p13 | 6/87 (6.9%) | 46/348 (13.2%) | 52/435 (12.0%) | .138 |
| t(4;14) | 22/103 (21.4%) | 75/421 (17.8%) | 97/524 (18.5%) | .399 |
| t(8;14) | 2/56 (3.6%) | 3/195 (1.5%) | 5/251 (2%) | .310 |
| t(14;16) | 17/91 (18.7%) | 34/391 (8.7%) | 51/482 (10.6%) | .008∗ |
| t(14;20) | 2/69 (2.9%) | 6/265 (2.3%) | 8/334 (2.4%) | .671 |
| Amplification of 1q | 43/85 (50.6) | 127/369 (34.4%) | 170/454 (37.4%) | .006∗ |
| Deletion of 1p | 6/75 (8%) | 46/351 (13.1%) | 52/426 (12.2%) | .250 |
| Deletion of 13q | 32/101 (31.7%) | 106/392 (27.0%) | 138/493 (28.0%) | .385 |
| Nonhyperdiploid | 105/123 (85.4%) | 467/525 (89.0%) | 572/648 (88.3%) | .277 |
The optimal cutoff for CTBP2 expression was determined using Cutoff Finder, as illustrated in Figure 1E.
The mean (range) is presented for continuous variables. Categorical variables were analyzed by Fisher exact test or χ2 test, and continuous variables were analyzed by unpaired t test.
BMPC, BM plasma cells; Hb, hemoglobin;, LDH lactate dehydrogenase; MMRF, Multiple Myeloma Research Foundation.
Statistically significant (P < .05).